MENU
+Compare
VRCA
Stock ticker: NASDAQ
AS OF
Dec 20, 04:59 PM (EDT)
Price
$0.70
Change
+$0.02 (+2.94%)
Capitalization
62.87M

VRCA Verrica Pharmaceuticals Forecast, Technical & Fundamental Analysis

a manufacturer of pharmaceutical products

Industry Biotechnology
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
a Summary for VRCA with price predictions
Dec 20, 2024

Momentum Indicator for VRCA turns negative, indicating new downward trend

VRCA saw its Momentum Indicator move below the 0 level on December 09, 2024. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 91 similar instances where the indicator turned negative. In of the 91 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VRCA turned negative on December 11, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRCA broke above its upper Bollinger Band on November 26, 2024. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where VRCA's RSI Indicator exited the oversold zone, of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in of 282 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: VRCA's P/B Ratio (149.254) is slightly higher than the industry average of (14.538). P/E Ratio (0.000) is within average values for comparable stocks, (87.654). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.759). VRCA has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (3.508) is also within normal values, averaging (254.760).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VRCA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

VRCA is expected to report earnings to fall 30.23% to -30 cents per share on February 27

Verrica Pharmaceuticals VRCA Stock Earnings Reports
Q4'24
Est.
$-0.30
Q3'24
Missed
by $0.05
Q2'24
Beat
by $0.04
Q1'24
Beat
by $0.05
Q4'23
Beat
by $0.03
The last earnings report on November 04 showed earnings per share of -43 cents, missing the estimate of -37 cents. With 1.54M shares outstanding, the current market capitalization sits at 62.87M.
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
44 West Gay Street
Phone
+1 484 453-3300
Employees
100
Web
https://www.verrica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GRRR13.370.64
+4.99%
Gorilla Technology Group
NVCR30.800.40
+1.32%
NovoCure Limited
NL7.960.06
+0.76%
NL Industries
BSX88.950.29
+0.33%
Boston Scientific Corp
MNSO23.34N/A
N/A
MINISO Group Holding Limited

VRCA and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, VRCA has been loosely correlated with TCBP. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VRCA jumps, then TCBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
+2.65%
TCBP - VRCA
41%
Loosely correlated
+1.35%
SCPX - VRCA
38%
Loosely correlated
-11.03%
ABCL - VRCA
33%
Loosely correlated
+4.80%
ACOG - VRCA
33%
Loosely correlated
+0.82%
PBYI - VRCA
31%
Poorly correlated
-0.90%
More